pre-seed
Stage
1
Investors
About
Axelyf develops RNA therapeutics for oncology and autoimmune diseases using a proprietary lipid nanoparticle delivery platform validated in non-human primates and optimized with AI to enable precise, potent drug delivery.
Explore Axelyf's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.